Three Hidden-Gem Small-Caps Flying Under the Radar While Everyone Watches SpaceX: UAMY, AGIO, and FMCB

Everyone's busy gawking at SpaceX's record-breaking IPO and refreshing their Micron earnings alerts. Meanwhile, $UAMY (US Antimony) is sitting on a $240 million sole-source government contract as the only North American antimony processor. Bloomberg Businessweek flagged a joint venture in Idaho with America's Gold and Silver ramping domestic production — and with critical minerals suddenly a national security obsession in Washington, this ~$100M market cap company is a rounding error compared to the contract on its books. The catalyst? Any legislative push on domestic critical mineral sourcing turns this into a screaming buy overnight.

Next up: $AGIO (Agios Pharmaceuticals), a rare disease biotech that shed its oncology assets to go all-in on hematology. With two approved drugs — Pyrukynd and Tibsovo — and a pipeline laser-focused on conditions nobody else is treating, Agios is the kind of boring-until-it's-not story that Seth Klarman built Baupost on. Market cap sits comfortably under $3B. A label expansion or Phase 3 data drop could reprice this thing entirely.

Finally, $FMCB (Farmers & Merchants Bancorp) is arguably the dullest stock on NASDAQ — and that's exactly the point. One-hundred-plus consecutive years of dividend increases, a pristine balance sheet, near-zero analyst coverage, and a community banking model that prints money in any rate environment. With mortgage rates hitting a one-month low per Bloomberg's latest read, regional loan demand is quietly perking up. Sometimes the most contrarian move is buying the thing nobody can be bothered to tweet about.